

Additional Table 5. Characteristics of the 458 primary breast tumors correlated with *PIK3R1* expression status.

	Total population (%)	Number of patients (%)		<i>P</i> -value ^a
		<i>PIK3R1</i> underexpression	<i>PIK3R1</i> non-underexpression	
<i>Total</i>	458 (100.0)	283 (61.8)	175 (38.2)	
<i>Age</i>				
≤50	99 (21.6)	61 (61.6)	38 (38.4)	NS
>50	359 (78.4)	222 (61.8)	137 (38.2)	
<i>SBR histological grade</i> ^{b,c}				
I	58 (12.6)	23 (39.7)	35 (60.3)	<0.0000001
II	230 (50.2)	125 (54.3)	105 (45.7)	
III	161 (35.2)	127 (78.9)	34 (21.1)	
<i>Lymph node status</i> ^d				
0	120 (26.2)	82 (68.3)	38 (31.7)	0.013
1-3	237 (51.7)	131 (55.3)	106 (44.7)	
>3	100 (21.8)	69 (69.0)	31 (31.0)	
<i>Macroscopic tumor size</i> ^e				
≤25mm	223 (48.7)	139 (62.3)	84 (37.7)	NS
>25mm	227 (49.6)	140 (61.7)	87 (38.3)	
<i>ERα status</i>				
Negative	119 (26.0)	103 (86.6)	16 (13.4)	<0.0000001
Positive	339 (74.0)	180 (53.1)	159 (46.9)	
<i>PR status</i>				
Negative	195 (42.6)	156 (80.0)	39 (20.0)	<0.0000001
Positive	263 (57.4)	127 (48.3)	136 (51.7)	
<i>ERBB2 status</i>				
Negative	359 (78.4)	211 (58.8)	148 (41.2)	0.011
Positive	99 (21.6)	72 (72.7)	27 (27.3)	
<i>Molecular subtypes</i>				
HR- ERBB2-	69 (15.1)	61 (88.4)	8 (11.6)	<0.0000001
HR- ERBB2+	45 (9.8)	40 (88.9)	5 (11.1)	
HR+ ERBB2-	290 (63.3)	150 (51.7)	140 (48.3)	
HR+ ERBB2+	54 (11.8)	32 (59.3)	22 (40.7)	
<i>Patients treatments</i> ^f				
No adjuvant treatment	85 (19.3)	58 (68.2)	27 (31.8)	0.026
Chemotherapy	89 (20.2)	64 (71.9)	25 (28.1)	
Hormonotherapy	173 (39.3)	102 (59.0)	71 (41.0)	
Chemo and Hormonotherapy	93 (21.1)	49 (52.7)	44 (47.3)	
		10	8	

^aChi² test. NS: not significant.

^bScarff-Bloom-Richardson classification.

^cInformation available for 449 patients.

^dInformation available for 457 patients.

^eInformation available for 450 patients.

^fInformation available for 440 patients.